Andra AP fonden Has $11.93 Million Stock Position in Cencora, Inc. $COR

Andra AP fonden raised its position in shares of Cencora, Inc. (NYSE:COR) by 17.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,980 shares of the company’s stock after acquiring an additional 5,580 shares during the quarter. Andra AP fonden’s holdings in Cencora were worth $11,931,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Kemnay Advisory Services Inc. bought a new stake in Cencora during the 4th quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new position in shares of Cencora during the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new position in shares of Cencora during the fourth quarter valued at approximately $27,000. Archer Investment Corp grew its holdings in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC bought a new stake in Cencora during the fourth quarter worth $29,000. 97.52% of the stock is owned by institutional investors.

Insider Activity at Cencora

In other news, Director Lauren M. Tyler acquired 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.38% of the company’s stock.

Cencora Price Performance

Cencora stock opened at $303.27 on Wednesday. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. The business’s 50 day simple moving average is $281.69 and its 200 day simple moving average is $317.02. The company has a market cap of $59.00 billion, a price-to-earnings ratio of 23.26, a PEG ratio of 1.69 and a beta of 0.58.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same quarter in the previous year, the business earned $4.42 EPS. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its Board of Directors has initiated a share buyback plan on Thursday, May 21st that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio is currently 18.40%.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Evercore set a $360.00 price target on shares of Cencora in a research report on Wednesday, April 8th. Bank of America upped their price objective on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a research report on Wednesday, June 24th. Weiss Ratings lowered shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research report on Friday, May 8th. Finally, Citigroup cut their target price on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.